Philip E Castle

Summary

Publications

  1. doi request reprint Introduction of human papillomavirus DNA screening in the world: 15 years of experience
    Philip E Castle
    American Society for Clinical Pathology, Washington, DC, USA
    Vaccine 30:F117-22. 2012
  2. pmc The clinical meaning of a cervical intraepithelial neoplasia grade 1 biopsy
    Philip E Castle
    American Society for Clinical Pathology Institute, Washington, DC 20005, USA
    Obstet Gynecol 118:1222-9. 2011
  3. pmc Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up
    Philip E Castle
    American Society for Clinical Pathology, 1225 New York Ave NW, Suite 350, Washington, DC 20005, USA
    J Clin Oncol 30:3044-50. 2012
  4. pmc Evaluation of any or type-specific persistence of high-risk human papillomavirus for detecting cervical precancer
    Morgan A Marks
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
    J Clin Microbiol 50:300-6. 2012
  5. ncbi request reprint Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study
    Philip E Castle
    American Society for Clinical Pathology Institute, Washington, DC 20005, USA
    Lancet Oncol 12:880-90. 2011
  6. pmc Evaluation of a new DNA test for detection of carcinogenic human papillomavirus
    Philip E Castle
    American Society for Clinical Pathology, 1225 New York Ave NW, Suite 250, Washington, DC 20005, USA
    J Clin Microbiol 49:3029-32. 2011
  7. pmc Comparative community outreach to increase cervical cancer screening in the Mississippi Delta
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD, USA
    Prev Med 52:452-5. 2011
  8. pmc Human papillomavirus (HPV) genotypes in women with cervical precancer and cancer at Kaiser Permanente Northern California
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, Maryland, USA
    Cancer Epidemiol Biomarkers Prev 20:946-53. 2011
  9. pmc Risk factors for anal HPV infection and anal precancer in HIV-infected men who have sex with men
    Lauren M Schwartz
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville
    J Infect Dis 208:1768-75. 2013
  10. pmc Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections
    Ana Cecilia Rodriguez
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, EPS, Rm 5032, Rockville, MD 20852, USA
    J Natl Cancer Inst 100:513-7. 2008

Detail Information

Publications83

  1. doi request reprint Introduction of human papillomavirus DNA screening in the world: 15 years of experience
    Philip E Castle
    American Society for Clinical Pathology, Washington, DC, USA
    Vaccine 30:F117-22. 2012
    ..This article forms part of a special supplement entitled "Comprehensive Control of HPV Infections and Related Diseases" Vaccine Volume 30, Supplement 5, 2012...
  2. pmc The clinical meaning of a cervical intraepithelial neoplasia grade 1 biopsy
    Philip E Castle
    American Society for Clinical Pathology Institute, Washington, DC 20005, USA
    Obstet Gynecol 118:1222-9. 2011
    ..To determine whether the diagnosis of cervical intraepithelial neoplasia (CIN) grade 1 increases the risk of CIN 3 above what is observed for human papillomavirus (HPV) infection...
  3. pmc Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up
    Philip E Castle
    American Society for Clinical Pathology, 1225 New York Ave NW, Suite 350, Washington, DC 20005, USA
    J Clin Oncol 30:3044-50. 2012
    ..To describe the long-term (≥ 10 years) benefits of clinical human papillomavirus (HPV) DNA testing for cervical precancer and cancer risk prediction...
  4. pmc Evaluation of any or type-specific persistence of high-risk human papillomavirus for detecting cervical precancer
    Morgan A Marks
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
    J Clin Microbiol 50:300-6. 2012
    ..These trade-offs need to be considered when assessing the potential overall clinical utility of repeated testing for HR-HPV DNA to identify women at risk for CIN2/3...
  5. ncbi request reprint Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study
    Philip E Castle
    American Society for Clinical Pathology Institute, Washington, DC 20005, USA
    Lancet Oncol 12:880-90. 2011
    ..We did a subanalysis of this population to compare the screening performance of the cobas HPV test versus liquid-based cytology in women aged 25 years and older, and assess management strategies for HPV-positive women...
  6. pmc Evaluation of a new DNA test for detection of carcinogenic human papillomavirus
    Philip E Castle
    American Society for Clinical Pathology, 1225 New York Ave NW, Suite 250, Washington, DC 20005, USA
    J Clin Microbiol 49:3029-32. 2011
    ..We found comparable results with Hybrid Capture 2 (HC2) for detection of carcinogenic HPV (n = 473) and with Linear Array and Line Blot Assay (n = 371) for detection of individual HPV genotypes...
  7. pmc Comparative community outreach to increase cervical cancer screening in the Mississippi Delta
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD, USA
    Prev Med 52:452-5. 2011
    ..The aim of the study was to increase participation in cervical cancer screening of under-screened women living in the Mississippi Delta, a U.S. population at high risk for cervical cancer...
  8. pmc Human papillomavirus (HPV) genotypes in women with cervical precancer and cancer at Kaiser Permanente Northern California
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, Maryland, USA
    Cancer Epidemiol Biomarkers Prev 20:946-53. 2011
    ..Here, we present the HPV genotypes found in first ∼500 cases of cervical intraepithelial neoplasia grade 3 (CIN3) or more severe disease (CIN3+) diagnosed at the study baseline...
  9. pmc Risk factors for anal HPV infection and anal precancer in HIV-infected men who have sex with men
    Lauren M Schwartz
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville
    J Infect Dis 208:1768-75. 2013
    ..We evaluated risk factors for HPV infection and anal precancer in a population of HIV-infected MSM...
  10. pmc Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections
    Ana Cecilia Rodriguez
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, EPS, Rm 5032, Rockville, MD 20852, USA
    J Natl Cancer Inst 100:513-7. 2008
    ..These findings suggest that the medical community should emphasize persistence of cervical HPV infection, not single-time detection of HPV, in management strategies and health messages...
  11. pmc Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management
    Hormuzd A Katki
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health DHHS, Bethesda, MD 20892, USA
    J Low Genit Tract Dis 17:S78-84. 2013
    ..It is not clear how many negative posttreatment Pap or cotest results are needed to ensure adequate safety against CIN 2+ before returning to extended retesting intervals...
  12. pmc Follow-up testing after colposcopy: five-year risk of CIN 2+ after a colposcopic diagnosis of CIN 1 or less
    Hormuzd A Katki
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health DHHS, Bethesda, MD 20892, USA
    J Low Genit Tract Dis 17:S69-77. 2013
    ..An important question is how many subsequent negative Pap results, or negative Pap and human papillomavirus (HPV) cotest results, are needed before returning to an extended retesting interval...
  13. pmc Human papillomavirus testing in the prevention of cervical cancer
    Mark Schiffman
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
    J Natl Cancer Inst 103:368-83. 2011
    ..The greatest potential for reduction in cervical cancer rates from HPV screening is in low-resource regions that can implement infrequent rounds of low-cost HPV testing and treatment...
  14. ncbi request reprint Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis
    Mark E Sherman
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Natl Cancer Inst 95:46-52. 2003
    ..We evaluated whether simultaneous screening with a Pap test and human papillomavirus (HPV) testing is useful for assessing the risk for cervical intraepithelial neoplasia (CIN) 3 or cervical cancer...
  15. ncbi request reprint A population-based study of vaginal human papillomavirus infection in hysterectomized women
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892 7234, USA
    J Infect Dis 190:458-67. 2004
    ..e., A3/A4/A15) may have a predilection for vaginal epithelium...
  16. pmc Five-year risk of CIN 3+ to guide the management of women aged 21 to 24 years
    Hormuzd A Katki
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health DHHS, Bethesda, MD 20892, USA
    J Low Genit Tract Dis 17:S64-8. 2013
    ..To inform the management of Pap test abnormalities among women aged 21 to 24 years, who have extremely low cancer risks, we compared risks of CIN 3+ among women aged 21 to 24 versus 25 to 29 years or 30 to 64 years...
  17. pmc Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive
    Hormuzd A Katki
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health DHHS, Bethesda, MD 20892, USA
    J Low Genit Tract Dis 17:S56-63. 2013
    ..However, the performance of these guidelines in routine clinical practice has not been evaluated...
  18. pmc Five-year risks of CIN 3+ and cervical cancer among women with HPV testing of ASC-US Pap results
    Hormuzd A Katki
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health DHHS, Bethesda, MD 20892, USA
    J Low Genit Tract Dis 17:S36-42. 2013
    ..However, despite ample data, the routine clinical performance of HPV testing of women with ASC-US has not been adequately documented...
  19. pmc Five-year risks of CIN 3+ and cervical cancer among women with HPV-positive and HPV-negative high-grade Pap results
    Hormuzd A Katki
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health DHHS, Bethesda, MD 20892, USA
    J Low Genit Tract Dis 17:S50-5. 2013
    ..We examined whether HPV testing provides useful risk stratification in this context...
  20. pmc Five-year risks of CIN 2+ and CIN 3+ among women with HPV-positive and HPV-negative LSIL Pap results
    Hormuzd A Katki
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health DHHS, Bethesda, MD 20892, USA
    J Low Genit Tract Dis 17:S43-9. 2013
    ..Some authors have suggested that HPV triage might be effective at older ages, when the percentage of HPV positivity among women with LSIL declines...
  21. ncbi request reprint Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality
    Melinda Butsch Kovacic
    Division of Cancer Epidemiology and Genetics and Cancer Prevention Fellowship Program, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Cancer Res 66:10112-9. 2006
    ..The lack of evident severe abnormalities associated with HPV18 and related HPV types might have implications for screening for poorly detected glandular and alpha7-related lesions...
  22. ncbi request reprint The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice
    Michelle J Khan
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, Rm 7074, Rockville, MD 20852, USA
    J Natl Cancer Inst 97:1072-9. 2005
    ....
  23. pmc A comparison of cervical and vaginal human papillomavirus
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD 20892 7234, USA
    Sex Transm Dis 34:849-55. 2007
    ..Previous studies have failed to present data on or detect a broad spectrum of HPV genotypes and/or have not carefully sampled the vagina, instead relying on self-collection that is likely contaminated with cervical cells...
  24. pmc Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, DHHS, Bethesda, MD 20892, USA
    BMJ 339:b2569. 2009
    ....
  25. pmc Risk of precancer determined by HPV genotype combinations in women with minor cytologic abnormalities
    Julia C Gage
    Divisions of Cancer Epidemiology and Genetics and Cancer Prevention National Cancer Institute, Department of Health and Human Services, NIH, Bethesda, MD 20852, USA
    Cancer Epidemiol Biomarkers Prev 22:1095-101. 2013
    ..We evaluated genotyping for HPV16, HPV16/18, and HPV16/18/45 in carcinogenic HPV-positive women with atypical squamous cells of undetermined significance (ASCUS) and low-grade squamous intraepithelial lesion (LSIL) cytology...
  26. pmc Human papillomavirus genotype attribution and estimation of preventable fraction of anal intraepithelial neoplasia cases among HIV-infected men who have sex with men
    Vikrant V Sahasrabuddhe
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland 20852, USA
    J Infect Dis 207:392-401. 2013
    ....
  27. ncbi request reprint A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women
    Philip E Castle
    National Cancer Institute, Division of Cancer Epidemiology and Genetics, Bethesda, MD 20892, USA
    J Natl Cancer Inst 94:1406-14. 2002
    ..However, these potential risk factors have not been adequately studied in prospective studies...
  28. pmc A study of Amplicor human papillomavirus DNA detection in the atypical squamous cells of undetermined significance-low-grade squamous intraepithelial lesion triage study
    Nicolas Wentzensen
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20854 7234, USA
    Cancer Epidemiol Biomarkers Prev 18:1341-9. 2009
    ..Amplicor at the 1.5 cutoff had comparable performance with hc2. Whereas Amplicor missed more disease related to nontargeted types, hc2 was more likely to miss disease related to targeted types...
  29. pmc A comparison of linear array and hybrid capture 2 for detection of carcinogenic human papillomavirus and cervical precancer in ASCUS-LSIL triage study
    Patti E Gravitt
    Department of Epidemiology and Molecular Microbiology, Johns Hopkins University, Baltimore, Maryland, USA
    Cancer Epidemiol Biomarkers Prev 17:1248-54. 2008
    ..We were interested in comparing the performance of Linear Array (LA; Roche Molecular Systems) to Hybrid Capture 2 (hc2; Digene) for the detection of carcinogenic human papillomavirus (HPV) and cervical precancer...
  30. pmc Neither one-time negative screening tests nor negative colposcopy provides absolute reassurance against cervical cancer
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD 20892 7234, USA
    Int J Cancer 125:1649-56. 2009
    ....
  31. pmc Long-term persistence of prevalently detected human papillomavirus infections in the absence of detectable cervical precancer and cancer
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 7234, USA
    J Infect Dis 203:814-22. 2011
    ..Detailed descriptions of long-term persistence of human papillomavirus (HPV) in the absence of cervical precancer are lacking...
  32. ncbi request reprint Age-related changes of the cervix influence human papillomavirus type distribution
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute NIH, 6120 Executive Boulevard, Bethesda, MD 20892 7234, USA
    Cancer Res 66:1218-24. 2006
    ..These patterns need to be confirmed in other studies and populations. We suggest that these genetically distinct groups of HPV types may differ in tissue preferences, which may contribute to their differences in carcinogenic potential...
  33. pmc Comparative performance of human papillomavirus DNA testing using novel sample collection methods
    Julia C Gage
    Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, MSC 7231, Rockville, MD 20852, USA
    J Clin Microbiol 49:4185-9. 2011
    ..HC2 is likely more clinically specific, although possibly less sensitive, than either PCR test. Thus, use of HC2 on cervicovaginal specimens for screening could result in fewer referrals compared to LA and Amplicor...
  34. ncbi request reprint Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer Epidemiol Biomarkers Prev 11:1394-9. 2002
    ....
  35. pmc A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study
    Mark Schiffman
    Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Cancer Epidemiol Biomarkers Prev 20:1398-409. 2011
    ..Adding HPV testing to cytology is recommended for women ≥30 but long-term prospective studies of HPV testing are rare...
  36. ncbi request reprint A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892 7234, USA
    J Infect Dis 191:1808-16. 2005
    ..In some populations, HPV prevalence demonstrates a second peak in older women. Longitudinal data may help to explain this second peak...
  37. ncbi request reprint Human papillomavirus prevalence in women who have and have not undergone hysterectomies
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, MD, USA
    J Infect Dis 194:1702-5. 2006
    ..5% for WH) between the 2 groups of women. Although WH have a similar prevalence of carcinogenic HPV infection, compared with WNH without a cervix, they have minimal risk of HPV-induced cancer and are unlikely to benefit from HPV testing...
  38. ncbi request reprint Absolute risk of a subsequent abnormal pap among oncogenic human papillomavirus DNA-positive, cytologically negative women
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA
    Cancer 95:2145-51. 2002
    ..The absolute risk of a subsequent abnormal Pap test for these women is uncertain. Therefore, the proper counseling and clinical management of these women is also uncertain...
  39. ncbi request reprint Human papillomavirus testing following loop electrosurgical excision procedure identifies women at risk for posttreatment cervical intraepithelial neoplasia grade 2 or 3 disease
    Aimee R Kreimer
    National Cancer Institute, NIH, 6130 Executive Boulevard, Bethesda, MD 20892 7333, USA
    Cancer Epidemiol Biomarkers Prev 15:908-14. 2006
    ....
  40. pmc Comparison between prototype hybrid capture 3 and hybrid capture 2 human papillomavirus DNA assays for detection of high-grade cervical intraepithelial neoplasia and cancer
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    J Clin Microbiol 41:4022-30. 2003
    ..68 to 0.79). In conclusion, we suggest that HC3 (>/=0.6 RLU/PC) may be slightly more sensitive than and equally specific test as HC2 (>/=1.0 RLU/PC) for the detection of CIN3+ over the duration of typical screening intervals...
  41. pmc Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines
    Hormuzd A Katki
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health DHHS, Bethesda, MD 20892, USA
    J Low Genit Tract Dis 17:S28-35. 2013
    ..To promote management that is consistent with accepted practice, new guidelines incorporating cotesting should aim to achieve equal management of women at equal risk of cervical intraepithelial neoplasia grade 3 and cancer (CIN 3+)...
  42. pmc Human papillomavirus genotypes detected in clinician-collected and self-collected specimens from women living in the Mississippi Delta
    Philip E Castle
    Global Cancer Imitative, Chestertown, MD, USA
    BMC Infect Dis 13:5. 2013
    ..The aim of this analysis was to report the age-specific prevalence of HPV in this population...
  43. pmc Methylation of HPV18, HPV31, and HPV45 genomes and cervical intraepithelial neoplasia grade 3
    Nicolas Wentzensen
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, Room 5024, Rockville, MD 20852 7234, USA
    J Natl Cancer Inst 104:1738-49. 2012
    ..However, the extent of methylation in other HPV types and its role in progression to cancer is poorly understood...
  44. pmc Influence of loop electrosurgical excision procedure on subsequent acquisition of new human papillomavirus infections
    Philip E Castle
    Divisions of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    J Infect Dis 199:1612-20. 2009
    ..The impact of loop electrosurgical excision procedure (LEEP) treatment for cervical precancerous lesions on subsequent acquisition of new human papillomavirus (HPV) infections is not well described...
  45. pmc Comparison of the cobas Human Papillomavirus (HPV) test with the hybrid capture 2 and linear array HPV DNA tests
    Julia C Gage
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, DHHS, Bethesda, Maryland, USA
    J Clin Microbiol 50:61-5. 2012
    ..Additional studies are needed to compare HC2 and cobas for detecting and predicting CIN3 to understand the clinical implications of the discrepant test results between the two tests...
  46. doi request reprint Variable risk of cervical precancer and cancer after a human papillomavirus-positive test
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892 7234, USA
    Obstet Gynecol 117:650-6. 2011
    ..To explore the effect of screening history on the risk of cervical precancer and cancer after an human papillomavirus (HPV)-positive test...
  47. ncbi request reprint Immune profiling of plasma and cervical secretions using recycling immunoaffinity chromatography
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892 7234, USA
    Cancer Epidemiol Biomarkers Prev 12:1449-56. 2003
    ....
  48. pmc Hierarchical clustering of human papilloma virus genotype patterns in the ASCUS-LSIL triage study
    Nicolas Wentzensen
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland 20852 7234, USA
    Cancer Res 70:8578-86. 2010
    ..Our novel approach to study multiple genotype infections in cervical disease with the use of unsupervised hierarchical clustering can address complex genotype distributions on a population level...
  49. ncbi request reprint Smoking is a risk factor for cervical intraepithelial neoplasia grade 3 among oncogenic human papillomavirus DNA-positive women with equivocal or mildly abnormal cytology
    Kathleen McIntyre-Seltman
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Room 7074, 6120 Executive Boulevard, EPS MSC 7234, Bethesda, MD 20892 7234, USA
    Cancer Epidemiol Biomarkers Prev 14:1165-70. 2005
    ....
  50. ncbi request reprint Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD 20892 7234, USA
    J Natl Cancer Inst 97:1066-71. 2005
    ....
  51. pmc Comparison of two PCR-based human papillomavirus genotyping methods
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, Room 5004, EPS MSC 7234, Bethesda, MD 20892 7234
    J Clin Microbiol 46:3437-45. 2008
    ..Both approaches are suitable for monitoring the impact of HPV16/18 vaccines in clinical trials...
  52. ncbi request reprint Risk assessment to guide the prevention of cervical cancer
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892 7234, USA
    J Low Genit Tract Dis 12:1-7. 2008
    ....
  53. pmc Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice
    Hormuzd A Katki
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, DHHS, Bethesda, MD 20882, USA
    Lancet Oncol 12:663-72. 2011
    ....
  54. ncbi request reprint PCR testing of pooled longitudinally collected cervical specimens of women to increase the efficiency of studying human papillomavirus infection
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Room 7074, 6120 Executive Boulevard, EPS MSC 7234, Bethesda, MD 20892 7234, USA
    Cancer Epidemiol Biomarkers Prev 14:256-60. 2005
    ..7-91.4%), respectively. We conclude that pooling specimens and testing by PCR may be useful for discriminating HPV DNA-positive from completely negative specimen sets in women who are likely to have been HPV DNA-negative.>..
  55. pmc Comparison of measurements of human papillomavirus persistence for postcolposcopic surveillance for cervical precancerous lesions
    Julia C Gage
    Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Boulevard, EPS 7013, Rockville, MD 20852, USA
    Cancer Epidemiol Biomarkers Prev 19:1668-74. 2010
    ..Compared with pooled-probe testing, measuring HPV genotype-specific persistence might better predict subsequent grade 3 cervical intraepithelial neoplasia (CIN3)...
  56. doi request reprint The age-specific relationships of abnormal cytology and human papillomavirus DNA results to the risk of cervical precancer and cancer
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA
    Obstet Gynecol 116:76-84. 2010
    ..To estimate the relationship of human papillomavirus (HPV) detection and abnormal cytology with histologic diagnoses of cervical precancer and cancer...
  57. pmc A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia
    Mark Schiffman
    Divisions of Cancer Epidemiology and Genetics and Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20852, USA
    Cancer Res 70:3159-69. 2010
    ..Larger viral genomic studies are warranted, especially to identify the genetic basis for HPV16's unique carcinogenicity...
  58. doi request reprint Effect of the number of biopsies on the subsequent acquisition of new human papillomavirus infections
    Philip E Castle
    National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA
    Obstet Gynecol 114:1057-62. 2009
    ..To analyze the effect of number of biopsies taken at enrollment with incident human papillomavirus (HPV) infections detected at the next 6-month visit...
  59. ncbi request reprint Comparisons of HPV DNA detection by MY09/11 PCR methods
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892, USA
    J Med Virol 68:417-23. 2002
    ..Our data also suggest that studies reporting HPV DNA detection by PCR need to report the type of polymerase used, as well as other assay specifics, and underscore the need for worldwide standards of testing...
  60. pmc Comparison of ophthalmic sponges for measurements of immune markers from cervical secretions
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892 7234, USA
    Clin Diagn Lab Immunol 11:399-405. 2004
    ..These findings require confirmation...
  61. ncbi request reprint Human papillomavirus genotyping, human papillomavirus mRNA expression, and p16/Ki-67 cytology to detect anal cancer precursors in HIV-infected MSM
    Nicolas Wentzensen
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD 20852, USA
    AIDS 26:2185-92. 2012
    ..Both approaches have limited reproducibility and sensitivity for detecting anal cancer precursors. We evaluated biomarkers for human papillomavirus (HPV)-related disease in a population of HIV-infected MSM...
  62. ncbi request reprint Interlaboratory reliability of Hybrid Capture 2
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, DHHS, Bethesda, MD, USA
    Am J Clin Pathol 122:238-45. 2004
    ..73); among those with equivocal or abnormal cytologic findings, kappa values were 0.80 or more. These data show that HC2 is a reliable test for detecting clinically relevant oncogenic HPV DNA...
  63. pmc Comparison of linear array and line blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low-grade squamous intraepithelial lesion triage study
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, Room 5004, EPS MSC 7234, Bethesda, MD 20892 7234, USA
    J Clin Microbiol 46:109-17. 2008
    ..In conclusion, we found LA to be a promising assay for the detection of HPV genotypes and carcinogenic HPV, and it may be clinically useful for the detection of cervical precancer and cancer in women with equivocal cytology...
  64. pmc Human papillomavirus genotype specificity of hybrid capture 2
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, Room 5030, EPS MSC 7234, Bethesda, MD 20892 7234, USA
    J Clin Microbiol 46:2595-604. 2008
    ..In conclusion, hc2 cross-reacts with certain untargeted, noncarcinogenic HPV genotypes that are phylogenetically related to the targeted genotypes, but the degree of cross-reactivity may be less than previously reported...
  65. ncbi request reprint Polycyclic aromatic hydrocarbon-DNA adducts in cervix of women infected with carcinogenic human papillomavirus types: an immunohistochemistry study
    M Margaret Pratt
    Carcinogen DNA Interactions Section, LCBG, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA
    Mutat Res 624:114-23. 2007
    ..Therefore, PAH-DNA adduct formation as measured by this methodology did not appear related to the increased risk of cervical precancer and cancer among carcinogenic HPV-infected smokers...
  66. pmc Five-year experience of human papillomavirus DNA and Papanicolaou test cotesting
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA
    Obstet Gynecol 113:595-600. 2009
    ..To estimate the 5-year age group-specific test positives for Pap tests and human papillomavirus (HPV) testing in a large, general screening population of women 30 and older...
  67. ncbi request reprint Stability of archived liquid-based cervical cytologic specimens
    Philip E Castle
    The National Cancer Institute, Division of Cancer Epidemiology and Genetics, Rockville, Maryland 20892 7234, USA
    Cancer 99:89-96. 2003
    ..However, long-term DNA stability and cytologic stability of these biospecimens have not been evaluated...
  68. ncbi request reprint Hybrid capture 2 viral load and the 2-year cumulative risk of cervical intraepithelial neoplasia grade 3 or cancer
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA
    Am J Obstet Gynecol 191:1590-7. 2004
    ....
  69. pmc Comparative risk of high-grade histopathology diagnosis after a CIN 1 finding in endocervical curettage versus cervical biopsy
    Julia C Gage
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD 20892 7234, USA
    J Low Genit Tract Dis 17:137-41. 2013
    ..For women with these pathologic findings, we assessed their short-term risk of high-grade histopathologic diagnosis in the Calgary Health Region where ECC was routinely performed...
  70. ncbi request reprint A comparison of a prototype PCR assay and hybrid capture 2 for detection of carcinogenic human papillomavirus DNA in women with equivocal or mildly abnormal papanicolaou smears
    Mark Schiffman
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892 7234, USA
    Am J Clin Pathol 124:722-32. 2005
    ..Smaller amounts of material used in PCR could have limited its sensitivity, but our results demonstrate the importance of optimization and standardization of PCR-based assays for clinical applications...
  71. ncbi request reprint Viral determinants of human papillomavirus persistence following loop electrical excision procedure treatment for cervical intraepithelial neoplasia grade 2 or 3
    Aimee R Kreimer
    Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Cancer Epidemiol Biomarkers Prev 16:11-6. 2007
    ..Data from Atypical Squamous Cells of Undetermined Significance-Low-Grade Squamous Intraepithelial Lesion Triage Study were used to evaluate HPV persistence and reappearance after LEEP...
  72. pmc Detection of precancerous cervical lesions is differential by human papillomavirus type
    Mahboobeh Safaeian
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, Maryland, USA
    Cancer Res 69:3262-6. 2009
    ..001). These results indicate the underrepresentation of HPV18/45 in precancers, whereas HPV16-associated CIN3+ is diagnosed much earlier. Whether the underrepresentation of 18/45 may be due to occult pathology needs further investigation...
  73. pmc Human papillomavirus genotypes in cervical intraepithelial neoplasia grade 3
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Boulevard, Room 5004, MSC 7234, Bethesda, MD 20892 7234, USA
    Cancer Epidemiol Biomarkers Prev 19:1675-81. 2010
    ..There are few large case series describing the human papillomavirus (HPV) genotypes found in women diagnosed with rigorously reviewed cervical intraepithelial neoplasia grade 3 (CIN3), cervical precancer...
  74. pmc Factors influencing histologic confirmation of high-grade squamous intraepithelial lesion cytology
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA
    Obstet Gynecol 112:637-45. 2008
    ..To examine the predictors of histologic confirmation of high-grade squamous intraepithelial lesion (HSIL) cytology occurring in follow-up of young women originally referred into a trial because of less severe cytology...
  75. ncbi request reprint The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses: an ALTS report
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892 7234, USA
    Am J Clin Pathol 127:805-15. 2007
    ....
  76. ncbi request reprint Relationship of atypical glandular cell cytology, age, and human papillomavirus detection to cervical and endometrial cancer risks
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892 7234, USA
    Obstet Gynecol 115:243-8. 2010
    ....
  77. doi request reprint Etiologic heterogeneity for cervical carcinoma by histopathologic type, using comparative age-period-cohort models
    Laura L Reimers
    George Washington University School of Public Health and Human Services, Department of Pathology, Washington, DC, USA
    Cancer Epidemiol Biomarkers Prev 18:792-800. 2009
    ..Human papillomavirus (HPV) infections are causative for both types but the respective tumors may have different carcinogenic pathways...
  78. ncbi request reprint A novel filtration-based processing method of liquid cytology specimens for human papillomavirus DNA testing by hybrid capture II
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institute of Health, Department of Health and Human Services, Bethesda, MD 20892 7234, USA
    Am J Clin Pathol 123:250-5. 2005
    ..NPM reduces specimen handling and decreases total testing time by approximately 33% without significant losses in HCII test performance...
  79. ncbi request reprint Hormonal contraceptive use, pregnancy and parity, and the risk of cervical intraepithelial neoplasia 3 among oncogenic HPV DNA-positive women with equivocal or mildly abnormal cytology
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD 20892, USA
    Int J Cancer 117:1007-12. 2005
    ....
  80. doi request reprint An analysis of high-risk human papillomavirus DNA-negative cervical precancers in the ASCUS-LSIL Triage Study (ALTS)
    Philip E Castle
    Division of Cancer Epidemiology and Genetics and Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA
    Obstet Gynecol 111:847-56. 2008
    ....
  81. ncbi request reprint A cross-sectional study of a prototype carcinogenic human papillomavirus E6/E7 messenger RNA assay for detection of cervical precancer and cancer
    Philip E Castle
    Division of Cancer Epidemiology, National Cancer Institute, NIH, Department of Health and Human Services, Bethesda, Maryland 20892 7234, USA
    Clin Cancer Res 13:2599-605. 2007
    ..To evaluate carcinogenic human papillomavirus (HPV) mRNA for E6 and E7 mRNA detection on clinical specimens to identify women with cervical precancer and cancer...
  82. pmc Risk assessment to guide the prevention of cervical cancer
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892 7234, USA
    Am J Obstet Gynecol 197:356.e1-6. 2007
    ....
  83. pmc Pilot study of a commercialized human papillomavirus (HPV) genotyping assay: comparison of HPV risk group to cytology and histology
    Philip E Castle
    Division of Cancer Epidemiology, National Cancer Institute, NIH, DHHS, Bethesda, MD 20892 7234, USA
    J Clin Microbiol 44:3915-7. 2006
    ..0005) and histologic diagnoses (P(Trend) < 0.0005)...